Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries
•Differences exist regarding PCa characteristics in favorable and unfavorable IR PCa.•Differences in active treatment rates exist across SEER registries.•Differences in treatment rates are explained by differences in PCa characteristics. Intermediate risk (IR) prostate cancer (PCa) is a highly heter...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology 2021-10, Vol.74, p.101994-101994, Article 101994 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101994 |
|---|---|
| container_issue | |
| container_start_page | 101994 |
| container_title | Cancer epidemiology |
| container_volume | 74 |
| creator | Wenzel, Mike Collà Ruvolo, Claudia Nocera, Luigi Würnschimmel, Christoph Tian, Zhe Shariat, Shahrokh F. Saad, Fred Briganti, Alberto Graefen, Markus Becker, Andreas Mandel, Philipp Chun, Felix K.H. Karakiewicz, Pierre I. |
| description | •Differences exist regarding PCa characteristics in favorable and unfavorable IR PCa.•Differences in active treatment rates exist across SEER registries.•Differences in treatment rates are explained by differences in PCa characteristics.
Intermediate risk (IR) prostate cancer (PCa) is a highly heterogeneous entity and can be distinguished into favorable and unfavorable IR PCa according to biopsy, PSA and cT-stage characteristics. These differences may translate into differences in treatment type.
We tested for differences in PCa tumor characteristics and differences in active treatment rates (radical prostatectomy [RP], external beam radiotherapy [EBRT]) according to Surveillance, Epidemiology and End Results (SEER) registry (2010−2015) in favorable and unfavorable IR PCa. Data were stratified according to individual SEER registries. Further analyses additionally adjusted for PCa baseline characteristics (PSA, cT stage, biopsy Gleason group grading [GGG], percentage of positive biopsy cores).
Tabulations according to SEER registries showed that, in favorable IR vs. unfavorable IR, the rates of RP and EBRT respectively ranged from 30.0 to 54.3% vs. 30.3–55.5 % and 8.3–44.7 % vs. 11.5–45.5 %. Differences in age and baseline PCa tumor characteristics also existed in both favorable and unfavorable IR across SEER registries. After adjustment for those baseline patient and PCa characteristics (PSA, cT stage, GGG, percentage of positive biopsy cores), RP and EBRT rates exhibited virtually no residual differences across individual SEER registries, in both favorable (36.0–41.0 % and 26.8–28.1 %) and unfavorable IR PCa (39.2−42.0% and 31.1–33.5 %).
Important differences may be identified in treatment rates within the examined 18 SEER registries in favorable and in unfavorable IR PCa. However, the observed differences are virtually entirely explained by differences in baseline PCa characteristics. |
| doi_str_mv | 10.1016/j.canep.2021.101994 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2559434228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782121001119</els_id><sourcerecordid>2559434228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-89a5166c4a2f90918d825968614bd2f58492fa956e3b3670e9f6b1d199aac8213</originalsourceid><addsrcrecordid>eNp9Uc2KFDEQDqLgOvoEXgJevMyYpLvTycGDLOMPLAi7LngLNUllzdidHpPMgg_pO5nuFgUFT0kq309VfYQ852zHGZevjjsLEU87wQSfK1q3D8gFV32_7VXz-eHvu-CPyZOcj4xJyXl3QX5c412YIgzUBe8xYbSYaYj0BCVgLBTukEJ09JSmXKAgrU4WE7VfIIEtmEIuweYFk-p_ppOnJSGUcaaPk4MhVKlF1MP9lOAwrJLn-OcdYpUa0YXZomp-_ccQbC1kehtDQUdvyuJ1s99f01RHyCVVj6fkkYch47Nf54bcvt1_uny_vfr47sPlm6utbWRbtkpDx6W0LQivmebKKdFpqSRvD074TrVaeNCdxObQyJ6h9vLAXV0rgK07bDbk5apbm_x2xlzMGLLFYagpTOdsRNfptmmFUBX64i_ocTqnuvAZ1TctV6xCN6RZUcuQCb05pTBC-m44M3PE5miWiM0csVkjrqzXKwvrrPcBk8k2zAm6kNAW46bwX_5PKzm0vg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2573418094</pqid></control><display><type>article</type><title>Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries</title><source>Elsevier ScienceDirect Journals</source><creator>Wenzel, Mike ; Collà Ruvolo, Claudia ; Nocera, Luigi ; Würnschimmel, Christoph ; Tian, Zhe ; Shariat, Shahrokh F. ; Saad, Fred ; Briganti, Alberto ; Graefen, Markus ; Becker, Andreas ; Mandel, Philipp ; Chun, Felix K.H. ; Karakiewicz, Pierre I.</creator><creatorcontrib>Wenzel, Mike ; Collà Ruvolo, Claudia ; Nocera, Luigi ; Würnschimmel, Christoph ; Tian, Zhe ; Shariat, Shahrokh F. ; Saad, Fred ; Briganti, Alberto ; Graefen, Markus ; Becker, Andreas ; Mandel, Philipp ; Chun, Felix K.H. ; Karakiewicz, Pierre I.</creatorcontrib><description>•Differences exist regarding PCa characteristics in favorable and unfavorable IR PCa.•Differences in active treatment rates exist across SEER registries.•Differences in treatment rates are explained by differences in PCa characteristics.
Intermediate risk (IR) prostate cancer (PCa) is a highly heterogeneous entity and can be distinguished into favorable and unfavorable IR PCa according to biopsy, PSA and cT-stage characteristics. These differences may translate into differences in treatment type.
We tested for differences in PCa tumor characteristics and differences in active treatment rates (radical prostatectomy [RP], external beam radiotherapy [EBRT]) according to Surveillance, Epidemiology and End Results (SEER) registry (2010−2015) in favorable and unfavorable IR PCa. Data were stratified according to individual SEER registries. Further analyses additionally adjusted for PCa baseline characteristics (PSA, cT stage, biopsy Gleason group grading [GGG], percentage of positive biopsy cores).
Tabulations according to SEER registries showed that, in favorable IR vs. unfavorable IR, the rates of RP and EBRT respectively ranged from 30.0 to 54.3% vs. 30.3–55.5 % and 8.3–44.7 % vs. 11.5–45.5 %. Differences in age and baseline PCa tumor characteristics also existed in both favorable and unfavorable IR across SEER registries. After adjustment for those baseline patient and PCa characteristics (PSA, cT stage, GGG, percentage of positive biopsy cores), RP and EBRT rates exhibited virtually no residual differences across individual SEER registries, in both favorable (36.0–41.0 % and 26.8–28.1 %) and unfavorable IR PCa (39.2−42.0% and 31.1–33.5 %).
Important differences may be identified in treatment rates within the examined 18 SEER registries in favorable and in unfavorable IR PCa. However, the observed differences are virtually entirely explained by differences in baseline PCa characteristics.</description><identifier>ISSN: 1877-7821</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2021.101994</identifier><language>eng</language><publisher>New York: Elsevier Ltd</publisher><subject>Biopsy ; Cancer ; Cancer surgery ; Cancer therapies ; Cores ; Epidemiology ; Favorable ; Geography ; Health risks ; Intermediate risk ; Patients ; Prostate cancer ; Prostatectomy ; Radiation therapy ; Regional differences ; Registries ; Surveillance ; Treatment variability ; Tumors ; Unfavorable ; United States ; Urological surgery</subject><ispartof>Cancer epidemiology, 2021-10, Vol.74, p.101994-101994, Article 101994</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c364t-89a5166c4a2f90918d825968614bd2f58492fa956e3b3670e9f6b1d199aac8213</citedby><cites>FETCH-LOGICAL-c364t-89a5166c4a2f90918d825968614bd2f58492fa956e3b3670e9f6b1d199aac8213</cites><orcidid>0000-0002-4338-0889 ; 0000-0003-3354-8139</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1877782121001119$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Wenzel, Mike</creatorcontrib><creatorcontrib>Collà Ruvolo, Claudia</creatorcontrib><creatorcontrib>Nocera, Luigi</creatorcontrib><creatorcontrib>Würnschimmel, Christoph</creatorcontrib><creatorcontrib>Tian, Zhe</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>Becker, Andreas</creatorcontrib><creatorcontrib>Mandel, Philipp</creatorcontrib><creatorcontrib>Chun, Felix K.H.</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><title>Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries</title><title>Cancer epidemiology</title><description>•Differences exist regarding PCa characteristics in favorable and unfavorable IR PCa.•Differences in active treatment rates exist across SEER registries.•Differences in treatment rates are explained by differences in PCa characteristics.
Intermediate risk (IR) prostate cancer (PCa) is a highly heterogeneous entity and can be distinguished into favorable and unfavorable IR PCa according to biopsy, PSA and cT-stage characteristics. These differences may translate into differences in treatment type.
We tested for differences in PCa tumor characteristics and differences in active treatment rates (radical prostatectomy [RP], external beam radiotherapy [EBRT]) according to Surveillance, Epidemiology and End Results (SEER) registry (2010−2015) in favorable and unfavorable IR PCa. Data were stratified according to individual SEER registries. Further analyses additionally adjusted for PCa baseline characteristics (PSA, cT stage, biopsy Gleason group grading [GGG], percentage of positive biopsy cores).
Tabulations according to SEER registries showed that, in favorable IR vs. unfavorable IR, the rates of RP and EBRT respectively ranged from 30.0 to 54.3% vs. 30.3–55.5 % and 8.3–44.7 % vs. 11.5–45.5 %. Differences in age and baseline PCa tumor characteristics also existed in both favorable and unfavorable IR across SEER registries. After adjustment for those baseline patient and PCa characteristics (PSA, cT stage, GGG, percentage of positive biopsy cores), RP and EBRT rates exhibited virtually no residual differences across individual SEER registries, in both favorable (36.0–41.0 % and 26.8–28.1 %) and unfavorable IR PCa (39.2−42.0% and 31.1–33.5 %).
Important differences may be identified in treatment rates within the examined 18 SEER registries in favorable and in unfavorable IR PCa. However, the observed differences are virtually entirely explained by differences in baseline PCa characteristics.</description><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer surgery</subject><subject>Cancer therapies</subject><subject>Cores</subject><subject>Epidemiology</subject><subject>Favorable</subject><subject>Geography</subject><subject>Health risks</subject><subject>Intermediate risk</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Radiation therapy</subject><subject>Regional differences</subject><subject>Registries</subject><subject>Surveillance</subject><subject>Treatment variability</subject><subject>Tumors</subject><subject>Unfavorable</subject><subject>United States</subject><subject>Urological surgery</subject><issn>1877-7821</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9Uc2KFDEQDqLgOvoEXgJevMyYpLvTycGDLOMPLAi7LngLNUllzdidHpPMgg_pO5nuFgUFT0kq309VfYQ852zHGZevjjsLEU87wQSfK1q3D8gFV32_7VXz-eHvu-CPyZOcj4xJyXl3QX5c412YIgzUBe8xYbSYaYj0BCVgLBTukEJ09JSmXKAgrU4WE7VfIIEtmEIuweYFk-p_ppOnJSGUcaaPk4MhVKlF1MP9lOAwrJLn-OcdYpUa0YXZomp-_ccQbC1kehtDQUdvyuJ1s99f01RHyCVVj6fkkYch47Nf54bcvt1_uny_vfr47sPlm6utbWRbtkpDx6W0LQivmebKKdFpqSRvD074TrVaeNCdxObQyJ6h9vLAXV0rgK07bDbk5apbm_x2xlzMGLLFYagpTOdsRNfptmmFUBX64i_ocTqnuvAZ1TctV6xCN6RZUcuQCb05pTBC-m44M3PE5miWiM0csVkjrqzXKwvrrPcBk8k2zAm6kNAW46bwX_5PKzm0vg</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Wenzel, Mike</creator><creator>Collà Ruvolo, Claudia</creator><creator>Nocera, Luigi</creator><creator>Würnschimmel, Christoph</creator><creator>Tian, Zhe</creator><creator>Shariat, Shahrokh F.</creator><creator>Saad, Fred</creator><creator>Briganti, Alberto</creator><creator>Graefen, Markus</creator><creator>Becker, Andreas</creator><creator>Mandel, Philipp</creator><creator>Chun, Felix K.H.</creator><creator>Karakiewicz, Pierre I.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4338-0889</orcidid><orcidid>https://orcid.org/0000-0003-3354-8139</orcidid></search><sort><creationdate>202110</creationdate><title>Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries</title><author>Wenzel, Mike ; Collà Ruvolo, Claudia ; Nocera, Luigi ; Würnschimmel, Christoph ; Tian, Zhe ; Shariat, Shahrokh F. ; Saad, Fred ; Briganti, Alberto ; Graefen, Markus ; Becker, Andreas ; Mandel, Philipp ; Chun, Felix K.H. ; Karakiewicz, Pierre I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-89a5166c4a2f90918d825968614bd2f58492fa956e3b3670e9f6b1d199aac8213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer surgery</topic><topic>Cancer therapies</topic><topic>Cores</topic><topic>Epidemiology</topic><topic>Favorable</topic><topic>Geography</topic><topic>Health risks</topic><topic>Intermediate risk</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Radiation therapy</topic><topic>Regional differences</topic><topic>Registries</topic><topic>Surveillance</topic><topic>Treatment variability</topic><topic>Tumors</topic><topic>Unfavorable</topic><topic>United States</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wenzel, Mike</creatorcontrib><creatorcontrib>Collà Ruvolo, Claudia</creatorcontrib><creatorcontrib>Nocera, Luigi</creatorcontrib><creatorcontrib>Würnschimmel, Christoph</creatorcontrib><creatorcontrib>Tian, Zhe</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>Becker, Andreas</creatorcontrib><creatorcontrib>Mandel, Philipp</creatorcontrib><creatorcontrib>Chun, Felix K.H.</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wenzel, Mike</au><au>Collà Ruvolo, Claudia</au><au>Nocera, Luigi</au><au>Würnschimmel, Christoph</au><au>Tian, Zhe</au><au>Shariat, Shahrokh F.</au><au>Saad, Fred</au><au>Briganti, Alberto</au><au>Graefen, Markus</au><au>Becker, Andreas</au><au>Mandel, Philipp</au><au>Chun, Felix K.H.</au><au>Karakiewicz, Pierre I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries</atitle><jtitle>Cancer epidemiology</jtitle><date>2021-10</date><risdate>2021</risdate><volume>74</volume><spage>101994</spage><epage>101994</epage><pages>101994-101994</pages><artnum>101994</artnum><issn>1877-7821</issn><eissn>1877-783X</eissn><abstract>•Differences exist regarding PCa characteristics in favorable and unfavorable IR PCa.•Differences in active treatment rates exist across SEER registries.•Differences in treatment rates are explained by differences in PCa characteristics.
Intermediate risk (IR) prostate cancer (PCa) is a highly heterogeneous entity and can be distinguished into favorable and unfavorable IR PCa according to biopsy, PSA and cT-stage characteristics. These differences may translate into differences in treatment type.
We tested for differences in PCa tumor characteristics and differences in active treatment rates (radical prostatectomy [RP], external beam radiotherapy [EBRT]) according to Surveillance, Epidemiology and End Results (SEER) registry (2010−2015) in favorable and unfavorable IR PCa. Data were stratified according to individual SEER registries. Further analyses additionally adjusted for PCa baseline characteristics (PSA, cT stage, biopsy Gleason group grading [GGG], percentage of positive biopsy cores).
Tabulations according to SEER registries showed that, in favorable IR vs. unfavorable IR, the rates of RP and EBRT respectively ranged from 30.0 to 54.3% vs. 30.3–55.5 % and 8.3–44.7 % vs. 11.5–45.5 %. Differences in age and baseline PCa tumor characteristics also existed in both favorable and unfavorable IR across SEER registries. After adjustment for those baseline patient and PCa characteristics (PSA, cT stage, GGG, percentage of positive biopsy cores), RP and EBRT rates exhibited virtually no residual differences across individual SEER registries, in both favorable (36.0–41.0 % and 26.8–28.1 %) and unfavorable IR PCa (39.2−42.0% and 31.1–33.5 %).
Important differences may be identified in treatment rates within the examined 18 SEER registries in favorable and in unfavorable IR PCa. However, the observed differences are virtually entirely explained by differences in baseline PCa characteristics.</abstract><cop>New York</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.canep.2021.101994</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4338-0889</orcidid><orcidid>https://orcid.org/0000-0003-3354-8139</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-7821 |
| ispartof | Cancer epidemiology, 2021-10, Vol.74, p.101994-101994, Article 101994 |
| issn | 1877-7821 1877-783X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2559434228 |
| source | Elsevier ScienceDirect Journals |
| subjects | Biopsy Cancer Cancer surgery Cancer therapies Cores Epidemiology Favorable Geography Health risks Intermediate risk Patients Prostate cancer Prostatectomy Radiation therapy Regional differences Registries Surveillance Treatment variability Tumors Unfavorable United States Urological surgery |
| title | Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regional%20differences%20in%20patient%20age%20and%20prostate%20cancer%20characteristics%20and%20rates%20of%20treatment%20modalities%20in%20favorable%20and%20unfavorable%20intermediate%20risk%20prostate%20cancer%20across%20United%20States%20SEER%20registries&rft.jtitle=Cancer%20epidemiology&rft.au=Wenzel,%20Mike&rft.date=2021-10&rft.volume=74&rft.spage=101994&rft.epage=101994&rft.pages=101994-101994&rft.artnum=101994&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2021.101994&rft_dat=%3Cproquest_cross%3E2559434228%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2573418094&rft_id=info:pmid/&rft_els_id=S1877782121001119&rfr_iscdi=true |